- Home
- ACB vs ABEO Comparison
ACB vs ABEO Comparison
Compare ACB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- ABEO
- Stock Information
- Founded
- ACB 2013
- ABEO 1974
- Country
- ACB Canada
- ABEO United States
- Employees
- ACB N/A
- ABEO N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- ABEO Health Care
- Exchange
- ACB Nasdaq
- ABEO Nasdaq
- Market Cap
- ACB 264.2M
- ABEO 281.0M
- IPO Year
- ACB N/A
- ABEO 1980
- Fundamental
- Price
- ACB $4.43
- ABEO $4.55
- Analyst Decision
- ACB
- ABEO Strong Buy
- Analyst Count
- ACB 0
- ABEO 5
- Target Price
- ACB N/A
- ABEO $18.20
- AVG Volume (30 Days)
- ACB 1.1M
- ABEO 2.4M
- Earning Date
- ACB 11-05-2025
- ABEO 11-12-2025
- Dividend Yield
- ACB N/A
- ABEO N/A
- EPS Growth
- ACB N/A
- ABEO N/A
- EPS
- ACB N/A
- ABEO 1.29
- Revenue
- ACB $263,570,704.00
- ABEO $400,000.00
- Revenue This Year
- ACB $9.42
- ABEO N/A
- Revenue Next Year
- ACB $5.72
- ABEO $324.71
- P/E Ratio
- ACB N/A
- ABEO $3.52
- Revenue Growth
- ACB 23.89
- ABEO N/A
- 52 Week Low
- ACB $3.42
- ABEO $3.93
- 52 Week High
- ACB $6.91
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- ACB 35.99
- ABEO 41.55
- Support Level
- ACB $4.33
- ABEO $4.00
- Resistance Level
- ACB $4.76
- ABEO $5.60
- Average True Range (ATR)
- ACB 0.22
- ABEO 0.33
- MACD
- ACB -0.04
- ABEO -0.01
- Stochastic Oscillator
- ACB 14.50
- ABEO 33.64
About ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.